LYKALABS Stock Overview
A pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Lyka Labs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹158.15 |
| 52 Week High | ₹176.59 |
| 52 Week Low | ₹97.90 |
| Beta | 1.07 |
| 1 Month Change | 0.38% |
| 3 Month Change | 11.37% |
| 1 Year Change | 28.21% |
| 3 Year Change | -28.78% |
| 5 Year Change | 682.92% |
| Change since IPO | 33.46% |
Recent News & Updates
Recent updates
There's Reason For Concern Over Lyka Labs Limited's (NSE:LYKALABS) Massive 36% Price Jump
Aug 22
Shareholders May Be More Conservative With Lyka Labs Limited's (NSE:LYKALABS) CEO Compensation For Now
Aug 03Getting In Cheap On Lyka Labs Limited (NSE:LYKALABS) Is Unlikely
Apr 10Subdued Growth No Barrier To Lyka Labs Limited's (NSE:LYKALABS) Price
Jan 05We Think Lyka Labs (NSE:LYKALABS) Has A Fair Chunk Of Debt
Nov 21These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Extensively
Jun 08A Look At The Fair Value Of Lyka Labs Limited (NSE:LYKALABS)
Mar 15Unpleasant Surprises Could Be In Store For Lyka Labs Limited's (NSE:LYKALABS) Shares
Aug 25Is Lyka Labs (NSE:LYKALABS) A Risky Investment?
Jun 11These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well
Feb 21Statutory Profit Doesn't Reflect How Good Lyka Labs' (NSE:LYKALABS) Earnings Are
Nov 05These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well
Nov 03Shareholder Returns
| LYKALABS | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 5.5% | 1.7% | 0.2% |
| 1Y | 28.2% | 39.1% | 17.2% |
Return vs Industry: LYKALABS underperformed the Indian Pharmaceuticals industry which returned 39.1% over the past year.
Return vs Market: LYKALABS exceeded the Indian Market which returned 17.2% over the past year.
Price Volatility
| LYKALABS volatility | |
|---|---|
| LYKALABS Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: LYKALABS has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: LYKALABS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 423 | Kunal Gandhi | www.lykalabs.com |
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, nutraceuticals, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data.
Lyka Labs Limited Fundamentals Summary
| LYKALABS fundamental statistics | |
|---|---|
| Market cap | ₹5.64b |
| Earnings (TTM) | ₹32.76m |
| Revenue (TTM) | ₹1.27b |
172.3x
P/E Ratio4.5x
P/S RatioIs LYKALABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LYKALABS income statement (TTM) | |
|---|---|
| Revenue | ₹1.27b |
| Cost of Revenue | ₹547.26m |
| Gross Profit | ₹718.63m |
| Other Expenses | ₹685.87m |
| Earnings | ₹32.76m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 04, 2025
| Earnings per share (EPS) | 0.92 |
| Gross Margin | 56.77% |
| Net Profit Margin | 2.59% |
| Debt/Equity Ratio | 33.9% |
How did LYKALABS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 01:14 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lyka Labs Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|